Medicine
fromArs Technica
5 days agoClinical trial shows gene editing works for -Thalassaemia, too
An improved gene editing system reactivates a fetal hemoglobin gene to treat β-Thalassaemia, building on CRISPR's success with sickle-cell anemia.
Doctors predicted Wayne Frederick, the president of Howard University, wouldn't live past 8. Now he's 54. Frederick came to the U.S. from Trinidad and Tobago with a dream of finding a cure for his disease, sickle cell anemia, but detoured into higher ed administration. At an event hosted by the American Council on Education at Howard University this week, Frederick said CRISPR gene editing, a technology developed in academia, made his dream a reality.